A dose of the vaccine china
Convidecia (Ad5-nCoV) has shown 57.5% effectiveness against the symptomatic disease caused by the coronavirus and a
91.7% against severe disease, according to a study Phase 3 clinical published today in “The Lancet”.
The analysis was carried out from samples collected until January 15, 2021, so it does not evaluate the immune response against new variants of the COVID-19 like delta and omicron, said “The Lancet” in a statement.
28 days after inoculation of the vaccine, there were no serious adverse effects related to the preparation and no deaths among the trial participants.
Scientists have considered “severe disease” any of the following symptoms: “severe systemic disease, respiratory failure, evidence of ‘shock’, significant acute liver or kidney dysfunction, or admission to the intensive care unit.”
A group of 36,727 people randomly received the vaccine developed by the firm CanSino Biologics and the Beijing Institute of Biotechnology, or were injected with a placebo, in 66 centers of study in Argentina, Chile, Mexico, Pakistan and Russia.
As the phase 1 and 2 studies showed, the vaccine it was “well tolerated” by patients and produced “high levels” of antibodies.
“Our study suggests that one dose of Ad5-nCoV is highly effective against severe disease and potentially will help to ease the tremendous pressure that covid-19 has put on healthcare systems around the world “, affirmed the main person in charge of study, Scott Halpering, of the Canadian University of Dalhousie.
The researchers note at the same time that “more research is needed to determine the effectiveness and durability of Ad5-nCoV over a longer period of time, as well as its effectiveness against worrisome variants, including omicron.”
Convidecia has been approved for emergency use in ten countries, including Argentina, Chile, Mexico and Pakistan, while regulatory scrutiny is underway in Russia, notes “The Lancet.”
